Security Snapshot

Protagonist Therapeutics, Inc - Common Stock (PTGX) Institutional Ownership

CUSIP: 74366E102

13F Institutional Holders and Ownership History from Q3 2016 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

310

Shares (Excl. Options)

70,709,233

Price

$87.34

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock
Symbol
PTGX on Nasdaq
Shares outstanding
63,850,747
Price per share
$105.40
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
70,709,233
Total reported value
$6,175,381,025
% of total 13F portfolios
0.01%
Share change
-562,363
Value change
+$99,663,953
Number of holders
310
Price from insider filings
$105.40
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • PTGX - Protagonist Therapeutics, Inc - Common Stock is tracked under CUSIP 74366E102.
  • 310 institutions reported positions in Q4 2025.
  • 9 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 310 to 71 between Q4 2025 and Q1 2026.
  • Reported value moved from $6,175,381,025 to $130,112,971.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 310 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 74366E102?
CUSIP 74366E102 identifies PTGX - Protagonist Therapeutics, Inc - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Protagonist Therapeutics, Inc - Common Stock (PTGX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 14% -6.7% $569,681,692 -$33,813,734 8,575,669 -5.6% BlackRock, Inc. 30 Sep 2025
Farallon Capital Partners, L.P. 10% 0% $545,701,455 +$25,461,794 6,248,013 +4.9% Dapice Joshua J. 31 Dec 2025
RTW INVESTMENTS, LP 8.1% $405,989,003 5,059,053 RTW Investments, LP 31 Dec 2025
VANGUARD PORTFOLIO MANAGEMENT LLC 5.5% $372,379,781 3,533,015 Vanguard Portfolio Management 31 Mar 2026
VANGUARD CAPITAL MANAGEMENT LLC 5.1% $342,550,316 3,250,003 Vanguard Capital Management 31 Mar 2026
STATE STREET CORP 5.2% +20% $170,012,022 +$26,561,215 3,207,774 +19% STATE STREET CORPORATION 30 Jun 2025
WELLINGTON MANAGEMENT GROUP LLP 5.1% $254,506,696 3,171,423 Wellington Management Group LLP 31 Dec 2025
BIOTECHNOLOGY VALUE FUND L P 4.1% -22% $170,121,650 -$43,187,804 2,560,916 -20% BVF PARTNERS L P/IL 30 Sep 2025
Deep Track Capital, LP 2.8% -51% $113,973,353 -$101,924,147 1,715,691 -47% Deep Track Capital, LP 30 Sep 2025

As of 31 Dec 2025, 310 institutional investors reported holding 70,709,233 shares of Protagonist Therapeutics, Inc - Common Stock (PTGX). This represents 111% of the company’s total 63,850,747 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Protagonist Therapeutics, Inc - Common Stock (PTGX) together control 89% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 15% 9,715,999 +3.3% 0.01% $848,595,367
FARALLON CAPITAL MANAGEMENT LLC 9.6% 6,144,006 -0.84% 3.1% $536,617,484
VANGUARD GROUP INC 8.5% 5,413,690 +27% 0.01% $472,831,684
RTW INVESTMENTS, LP 7.9% 5,059,053 -12% 4.4% $441,857,689
STATE STREET CORP 5% 3,199,729 +1.1% 0.01% $279,464,331
WELLINGTON MANAGEMENT GROUP LLP 5% 3,171,423 +66% 0.05% $276,992,086
UBS Group AG 4.3% 2,770,021 +46% 0.05% $241,933,634
JANUS HENDERSON GROUP PLC 4.2% 2,649,981 +141% 0.1% $231,354,837
JOHNSON & JOHNSON 3.8% 2,449,183 0% 39% $213,911,643
Invesco Ltd. 2.5% 1,567,840 +56% 0.02% $136,935,146
GEODE CAPITAL MANAGEMENT, LLC 2.3% 1,452,928 +2.6% 0.01% $126,919,578
Woodline Partners LP 2.2% 1,408,772 -2% 0.48% $123,042,146
PRICE T ROWE ASSOCIATES INC /MD/ 2.2% 1,400,738 +15% 0.01% $122,341,000
PERCEPTIVE ADVISORS LLC 2.1% 1,350,425 +31% 2.2% $117,946,120
CITADEL ADVISORS LLC 1.8% 1,126,687 +374% 0.07% $98,404,842
Driehaus Capital Management LLC 1.7% 1,099,170 -3.6% 0.65% $96,001,508
ADAR1 Capital Management, LLC 1.6% 1,049,168 +6.1% 6.9% $91,634,333
MARSHALL WACE, LLP 1.6% 1,024,925 -5.6% 0.09% $89,516,950
GOLDMAN SACHS GROUP INC 1.5% 961,149 +23% 0.01% $83,946,754
MORGAN STANLEY 1.4% 879,024 +14% 0% $76,774,142
BANK OF AMERICA CORP /DE/ 1.4% 867,580 +4.5% 0.01% $75,774,437
NORTHERN TRUST CORP 0.9% 575,118 -4.7% 0.01% $50,230,807
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. 0.9% 571,825 4.4% $49,943,196
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.87% 556,762 +0.7% 0.01% $48,627,593
FMR LLC 0.85% 539,878 +3.7% 0% $47,152,926

Institutional Holders of Protagonist Therapeutics, Inc - Common Stock (PTGX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 1,235,079 $130,112,971 +$3,130,464 $105.40 71
2025 Q4 70,709,233 $6,175,381,025 +$99,663,953 $87.34 310
2025 Q3 70,684,460 $4,695,410,423 +$4,458,380 $66.43 274
2025 Q2 70,977,321 $3,923,985,934 +$344,775,786 $55.27 273
2025 Q1 64,994,031 $3,143,069,159 +$116,416,679 $48.36 273
2024 Q4 63,271,382 $2,442,272,169 +$44,242,054 $38.60 240
2024 Q3 61,602,509 $2,772,507,649 -$40,480,651 $45.00 238
2024 Q2 59,068,539 $2,046,920,014 -$15,105,959 $34.65 187
2024 Q1 59,715,204 $1,727,559,912 +$80,356,864 $28.93 183
2023 Q4 57,464,862 $1,317,641,644 +$12,220,647 $22.93 155
2023 Q3 56,712,373 $945,896,121 -$53,252,231 $16.68 142
2023 Q2 56,731,936 $1,566,841,397 +$104,873,016 $27.62 163
2023 Q1 53,194,090 $1,222,410,149 +$179,899,701 $23.00 135
2022 Q4 49,023,797 $534,831,663 +$12,387,471 $10.91 135
2022 Q3 47,348,207 $399,128,639 -$50,141,212 $8.43 129
2022 Q2 53,360,764 $422,090,018 -$73,694,821 $7.91 125
2022 Q1 50,329,296 $1,191,811,689 -$6,168,618 $23.68 136
2021 Q4 49,204,800 $1,682,561,970 +$93,460,895 $34.20 144
2021 Q3 46,239,107 $819,492,437 -$246,905,195 $17.72 126
2021 Q2 47,991,061 $2,154,082,054 +$179,883,058 $44.88 136
2021 Q1 44,189,630 $1,144,564,352 +$27,791,318 $25.90 124
2020 Q4 43,016,906 $867,295,836 +$98,827,896 $20.16 124
2020 Q3 37,171,432 $727,253,818 +$62,067,302 $19.55 91
2020 Q2 34,047,384 $601,265,429 +$210,058,150 $17.66 82
2020 Q1 23,373,035 $165,030,731 +$1,225,355 $7.06 75
2019 Q4 23,195,067 $163,521,727 +$7,867,560 $7.05 79
2019 Q3 18,937,325 $227,502,940 +$20,583,092 $12.01 74
2019 Q2 17,221,305 $208,468,560 +$25,952,329 $12.11 66
2019 Q1 15,062,271 $189,318,050 +$21,734,111 $12.57 64
2018 Q4 13,856,660 $93,215,143 -$9,989,308 $6.73 62
2018 Q3 16,027,640 $164,867,528 +$26,771,021 $10.29 60
2018 Q2 13,927,964 $93,611,738 +$10,872,610 $6.72 68
2018 Q1 11,933,401 $102,508,360 -$12,039,057 $8.59 67
2017 Q4 11,834,743 $246,147,238 +$77,189,243 $20.80 64
2017 Q3 8,125,676 $143,579,627 +$619,413 $17.67 41
2017 Q2 8,119,093 $91,824,177 -$276,502 $11.31 40
2017 Q1 8,008,863 $102,590,269 +$4,468,821 $12.81 39
2016 Q4 7,976,789 $174,812,982 +$2,372,202 $21.99 38
2016 Q3 6,904,061 $144,850,726 +$144,850,726 $21.13 34
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .